Sam Brusco, Associate Editor03.20.24
The ultimate goal for continuous glucose monitoring (CGM) and insulin pump technologies is to ease the diabetes struggle and manage the burdensome, chronic disease. CGM and insulin delivery technology is becoming smaller, smarter, and integrated to ease the burden of managing diabetes.
To get more information and insights about the technologies at the forefront of diabetes management, MPO recently spoke to Kevin Sayer, CEO of Dexcom.
Brusco: How does the Dexcom G7 CGM’s integration with the t:slim X2 AID fulfill unmet clinical needs for diabetes patients?
Kevin Sayer: For diabetes patients who rely on insulin multiple times a day, Dexcom’s newest integration with the Tandem t:slim X2 insulin pump not only offers users more choice and flexibility when it comes to how they deliver insulin, but it also means they can now use the world’s most accurate CGM, Dexcom G7, to manage their diabetes. The clinical benefits and increased peace of mind for users are clear. For instance, on a Tandem t:slim X2 insulin pump, Dexcom CGM users experience 11% more time in range. Furthermore, new results from the COMISAIR seven-year follow up—the longest prospective real-world CGM study ever conducted—also showed substantial reduction in HbA1c when a Dexcom CGM is connected to the Tandem t:slim X2 insulin pump with Control-IQ technology.
Brusco: Which continued unmet clinical needs does the company plan to pursue in the near future?
Kevin Sayer: Dexcom recently revealed that Stelo, its new glucose sensor, has received FDA approval and will launch in the U.S. this summer. Stelo will offer 15-day sensor wear, a cash-pay option, and a software experience tailored specifically for people with Type 2 diabetes who don’t use insulin, addressing a huge unmet need for this population of around 25 million people in the U.S. Building on Dexcom’s 25-year history making CGM technology that has revolutionized diabetes management, Stelo will open up innovative tech and critical insights to a new population looking to prevent chronic disease progression.
Brusco: What do you think will be the future (~5 years) for diabetes management technologies in general?
Kevin Sayer: We’re building a world in which our care for people includes not only the treatment of chronic conditions, but also the potential to prevent the onset of disease through better metabolic health for all. We continue to build our evidence base leveraging real-world data and claims analyses, as well as partnerships with several digital health companies. As we look at this tech and the benefits it has for people not using insulin, we believe there will be an opportunity down the road to extend the benefits of Dexcom’s sensing technology to help prevent the onset of diabetes and we are committed to getting our technology into the hands of as many people who can benefit from it as possible.
Brusco: Can you provide a short patient testimonial?
For more information about these technologies, check out the feature article "The Sweet Science of Diabetes Technology" featured in the March edition of MPO.